870310 | 16:0 Lyso PC-D9
1-hexadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine(d9)

Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
Info
16:0 Lyso PC-D9
1-hexadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine(d9)
16:0 Lyso PC, also known as 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, is a remarkable phospholipase-mediated hydrolyzed phosphocholine. This lipid features a saturated fatty acid—palmitic acid (16:0)—as its tail, which is generated through the hydrolysis of the sn-2 acyl chain of phosphatidylcholine (PC) by phospholipase A2. A crucial component of oxidized low-density lipoprotein, 16:0 Lyso PC plays a significant role in inflammatory diseases and atherosclerosis and is a substrate for Autotaxin/LysoPLD, generating lysophosphatidic acid, which is essential for cell motility. The versatility of 16:0 Lyso PC makes it a powerful tool in various advanced research and therapeutic applications. In microbubble-mediated drug delivery, it enhances the efficiency of targeted therapy applications, particularly in cancer treatment. By integrating into microbubble technologies, 16:0 Lyso PC facilitates precise drug delivery to target sites, optimizing therapeutic outcomes. Furthermore, its application in photodynamic therapy for glioma underscores its potential in medical treatments. Research has highlighted its role in biohybrid systems for light-activatable therapies, showing promise in treating challenging conditions like glioma. This innovative approach leverages 16:0 Lyso PC to improve clinical outcomes, showcasing its potential to enhance the effectiveness of photodynamic therapy. This product is deuterated which enables the study of structure, dynamics, and function of cell membranes. |
Data
No
No
C24H41D9NO7P |
>99%
1 year
-20°C
504.69
504.39